Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD

1.39  +0.02 (+1.46%)

After market: 1.41 +0.02 (+1.44%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INO. INO was compared to 558 industry peers in the Biotechnology industry. While INO seems to be doing ok healthwise, there are quite some concerns on its profitability. INO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INO had negative earnings in the past year.
INO had a negative operating cash flow in the past year.
In the past 5 years INO always reported negative net income.
In the past 5 years INO always reported negative operating cash flow.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -110.55%, INO is doing worse than 78.85% of the companies in the same industry.
Looking at the Return On Equity, with a value of -188.25%, INO is doing worse than 66.13% of the companies in the same industry.
Industry RankSector Rank
ROA -110.55%
ROE -188.25%
ROIC N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

5

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INO has been increased compared to 1 year ago.
INO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -30.28, we must say that INO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of INO (-30.28) is worse than 89.25% of its industry peers.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -30.28
ROIC/WACCN/A
WACC9.65%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

INO has a Current Ratio of 2.63. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.
INO has a worse Current ratio (2.63) than 67.92% of its industry peers.
INO has a Quick Ratio of 2.63. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.
INO's Quick ratio of 2.63 is on the low side compared to the rest of the industry. INO is outperformed by 66.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.63
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.32% over the past year.
Looking at the last year, INO shows a very negative growth in Revenue. The Revenue has decreased by -60.52% in the last year.
INO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -44.44% yearly.
EPS 1Y (TTM)44.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.7%
Revenue 1Y (TTM)-60.52%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A

3.2 Future

INO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.96% yearly.
INO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 356.19% yearly.
EPS Next Y48.64%
EPS Next 2Y24.44%
EPS Next 3Y21.09%
EPS Next 5Y17.96%
Revenue Next Year-37.05%
Revenue Next 2Y1041.17%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as INO's earnings are expected to grow with 21.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.44%
EPS Next 3Y21.09%

More info and screens

0

5. Dividend

5.1 Amount

INO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (7/18/2025, 8:00:02 PM)

After market: 1.41 +0.02 (+1.44%)

1.39

+0.02 (+1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-06 2025-08-06
Inst Owners37.34%
Inst Owner Change0%
Ins Owners0.74%
Ins Owner Change2.89%
Market Cap70.83M
Analysts80
Price Target7.65 (450.36%)
Short Float %10.86%
Short Ratio3.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.01%
Min EPS beat(2)29.03%
Max EPS beat(2)44.99%
EPS beat(4)3
Avg EPS beat(4)22.62%
Min EPS beat(4)-6.95%
Max EPS beat(4)44.99%
EPS beat(8)5
Avg EPS beat(8)10.42%
EPS beat(12)6
Avg EPS beat(12)4.5%
EPS beat(16)7
Avg EPS beat(16)-3.01%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.25%
PT rev (3m)-4.25%
EPS NQ rev (1m)1.59%
EPS NQ rev (3m)9.89%
EPS NY rev (1m)1.92%
EPS NY rev (3m)13.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-97.96%
Revenue NY rev (3m)-97.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 250.21
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-3.09
EYN/A
EPS(NY)-1.8
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS0.01
BVpS1.01
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.55%
ROE -188.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.83%
Cap/Sales 180.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.63
Altman-Z -30.28
F-Score1
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)16.84%
Cap/Depr(5y)25.5%
Cap/Sales(3y)90.66%
Cap/Sales(5y)72.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.7%
EPS Next Y48.64%
EPS Next 2Y24.44%
EPS Next 3Y21.09%
EPS Next 5Y17.96%
Revenue 1Y (TTM)-60.52%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A
Revenue Next Year-37.05%
Revenue Next 2Y1041.17%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%
EBIT growth 1Y10.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.5%
OCF growth 3YN/A
OCF growth 5YN/A